Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Clinical Trials topic
No spam. Unsubscribe anytime.
Lauderhill commission narrowly approves clinical-trials site on State Road 7 after extended debate
Summary
The City Commission approved a special-exception use allowing 4 41 Clinical Trials to operate a clinical-research site at 2451 N. State Road 7, with a close 3–2 vote after commissioners and residents questioned patient safety, staffing, consent and oversight.
The Lauderhill City Commission approved a special-exception use that will allow 4 41 Clinical Trials to operate a clinical-research site at 2451 North State Road 7 after a contested public hearing and extended commissioner questioning.
The vote on the application was 3–2. Commissioners approved the site-specific special-exception application that puts a clinical research presence — which the applicants described as a small outpatient site for phase‑2/3/4 studies — in an existing retail plaza located immediately north of Harney Rains Village Center.
Supporters argued the site will bring research access and potential treatments to local patients who meet study criteria. Applicant Molly DuBris, a local health‑care entrepreneur, said the business will provide screening, informed consent, and regulated enrollment for trials chosen and sponsored by pharmaceutical companies. Business‑development representative Brian Pestana and medical lead Dr. Rodney explained the facility would follow sponsor protocols, use Institutional Review Board (IRB) oversight and FDA‑approved study protocols, and limit daily patient visits to keep visits and staff workloads manageable.
Opponents and several commissioners pushed back on operational details. Commissioners and public commenters pressed the applicants on who would be present on site, how adverse events would be handled, protocols for screening and follow‑up, and whether a physician would be on site every day. The applicants said typical staffing would include a principal investigator (physician), a nurse, a medical aide and administrative personnel, and that protocols specify observation time, emergency procedures and sponsor oversight. The applicants told the commission they would not begin enrolling subjects until individual study protocols were approved by the sponsor and IRB and required state notifications were in place.
Public commenters expressed concerns about protections for vulnerable people, the potential for recruitment pressure in lower‑income neighborhoods, and whether the city should allow private clinical research sites to operate in retail settings. The City Commission heard both residents who supported greater research access and those who said the record supplied insufficient detail about day‑to‑day safety and oversight.
After questions from the dais and public comment, the commission voted to approve the special‑exception use. The commission recorded a split decision, with the ordinance granting the special exception to 4 41 Clinical Trials to operate at 2451 N. State Road 7.
The approval includes the conditions normally applied to special‑exception uses and relies on state and federal oversight (sponsor/IRB/FDA) for clinical protocols. The city will monitor permitting, building and business licensing steps that follow this land‑use approval.
The applicants were told to confirm physician availability and operational details during the building and licensing process. Commissioners emphasized the applicants must comply with all state and federal requirements before any human subjects work begins.
Commission action: approved 3–2.
What's next: The applicants must secure any required state notifications and IRB approvals, complete building/occupancy and business licensing, and comply with any conditions the city attaches to the certificate of use before enrolling subjects.
